SI2726101T1 - Inhibitorji aktivacije T-celic - Google Patents
Inhibitorji aktivacije T-celicInfo
- Publication number
- SI2726101T1 SI2726101T1 SI201231438T SI201231438T SI2726101T1 SI 2726101 T1 SI2726101 T1 SI 2726101T1 SI 201231438 T SI201231438 T SI 201231438T SI 201231438 T SI201231438 T SI 201231438T SI 2726101 T1 SI2726101 T1 SI 2726101T1
- Authority
- SI
- Slovenia
- Prior art keywords
- inhibitors
- cell activation
- activation
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503282P | 2011-06-30 | 2011-06-30 | |
EP12804528.3A EP2726101B1 (en) | 2011-06-30 | 2012-06-29 | Inhibitors of t-cell activation |
PCT/US2012/045017 WO2013003761A1 (en) | 2011-06-30 | 2012-06-29 | Inhibitors of t-cell activation |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2726101T1 true SI2726101T1 (sl) | 2018-12-31 |
Family
ID=47424568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231438T SI2726101T1 (sl) | 2011-06-30 | 2012-06-29 | Inhibitorji aktivacije T-celic |
Country Status (34)
Country | Link |
---|---|
US (3) | US9834604B2 (sl) |
EP (2) | EP3357511B1 (sl) |
JP (4) | JP6157461B2 (sl) |
KR (1) | KR20140058532A (sl) |
CN (2) | CN103796681B (sl) |
AU (3) | AU2012275133B2 (sl) |
BR (1) | BR112013033661A2 (sl) |
CA (1) | CA2839462A1 (sl) |
CL (1) | CL2013003725A1 (sl) |
CO (1) | CO6841996A2 (sl) |
CR (1) | CR20130661A (sl) |
DK (2) | DK2726101T3 (sl) |
DO (1) | DOP2013000313A (sl) |
ES (2) | ES2694749T3 (sl) |
GT (1) | GT201300323A (sl) |
HK (1) | HK1258401A1 (sl) |
HR (1) | HRP20181786T1 (sl) |
HU (1) | HUE040455T2 (sl) |
LT (1) | LT2726101T (sl) |
MA (1) | MA35280B1 (sl) |
MX (1) | MX354922B (sl) |
MY (1) | MY180616A (sl) |
NI (1) | NI201300140A (sl) |
PE (1) | PE20141469A1 (sl) |
PL (2) | PL2726101T3 (sl) |
PT (2) | PT2726101T (sl) |
RS (1) | RS57996B1 (sl) |
RU (1) | RU2657440C2 (sl) |
SG (1) | SG10201604715VA (sl) |
SI (1) | SI2726101T1 (sl) |
TN (1) | TN2013000532A1 (sl) |
UA (1) | UA116191C2 (sl) |
WO (1) | WO2013003761A1 (sl) |
ZA (1) | ZA201309532B (sl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
MX354922B (es) | 2011-06-30 | 2018-03-26 | Genzyme Corp | Inhibidores de la activación de las células t. |
US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
AU2013359907B2 (en) | 2012-12-11 | 2018-01-18 | Albert Einstein College Of Medicine, Inc. | Methods for high throughput receptor:ligand identification |
GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
IL247715B (en) | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
AU2015260230A1 (en) * | 2014-05-13 | 2016-11-17 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
JP6830437B2 (ja) | 2014-12-10 | 2021-02-17 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織および臓器 |
CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
CN107969128A (zh) * | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JO3736B1 (ar) | 2015-07-30 | 2021-01-31 | Macrogenics Inc | جزيئات رابطة لـ pd-1 وطرق استخدامها |
CN108513576A (zh) * | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
MX2018007089A (es) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. |
KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
JP7000322B2 (ja) | 2015-12-16 | 2022-02-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗lag3抗体および抗原結合性フラグメント |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
AU2017226269B2 (en) * | 2016-03-02 | 2021-10-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
WO2017180420A1 (en) * | 2016-04-11 | 2017-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CA3043630A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
KR102619015B1 (ko) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
EP3697810A2 (en) | 2017-10-18 | 2020-08-26 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
EP3716949A4 (en) * | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | METHODS OF TREATING AN AUTOIMMUNE DISEASE |
CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
WO2019151392A1 (ja) | 2018-01-31 | 2019-08-08 | 国立大学法人東北大学 | 抗原特異的mhc発現調節法 |
MX2020012124A (es) * | 2018-05-14 | 2021-04-19 | Immunocore Ltd | Polipeptidos de unión bifuncional. |
AU2020389422A1 (en) * | 2019-11-20 | 2022-06-02 | Gi Cell, Inc. | Medium composition for culturing T cells and method for culturing T cells using same |
EP4149534A2 (en) | 2020-05-12 | 2023-03-22 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
CN114805591A (zh) * | 2022-03-31 | 2022-07-29 | 浙江大学 | 靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用 |
WO2024036287A1 (en) * | 2022-08-12 | 2024-02-15 | Abata Therapeutics, Inc. | Stable regulatory t cells and methods of production |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
US6482925B1 (en) | 1996-11-28 | 2002-11-19 | Applied Research Systems Ars Holding N.V. | Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
WO2004076488A1 (en) * | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
ES2439580T3 (es) * | 2003-02-28 | 2014-01-23 | The Johns Hopkins University | Regulación de células T |
EP1755626A4 (en) * | 2004-05-17 | 2008-10-01 | Univ Illinois | USES OF BISPECIFIC ANTIBODIES (BIAB) COATED DENDRITIC CELLS WITH ANY OTHER PULSE |
US20090252741A1 (en) * | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
PL2229956T3 (pl) | 2004-09-13 | 2013-09-30 | Genzyme Corp | Konstrukty multimeryczne |
WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
JP2010529859A (ja) * | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | TGF−βII型受容体の2つのTGF−β結合ドメインを含有する融合タンパク質 |
WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
EP2257624B9 (en) | 2008-02-05 | 2012-08-01 | Medical Research Council | Methods and compositions |
JP2011512417A (ja) * | 2008-02-20 | 2011-04-21 | ジェンザイム・コーポレーション | 血管形成の阻害 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
MX354922B (es) | 2011-06-30 | 2018-03-26 | Genzyme Corp | Inhibidores de la activación de las células t. |
-
2012
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Application Discontinuation
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/en active Application Filing
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/en active Active
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 CA CA2839462A patent/CA2839462A1/en not_active Abandoned
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/en active Active
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
-
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
-
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
-
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
-
2018
- 2018-10-30 HR HRP20181786TT patent/HRP20181786T1/hr unknown
-
2019
- 2019-01-17 HK HK19100808.1A patent/HK1258401A1/zh unknown
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
-
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US20210380686A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258401A1 (zh) | T細胞活化的抑制劑 | |
HK1200371A1 (en) | Neprilysin inhibitors | |
EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
ZA201303433B (en) | Inhibitors of hiv replication | |
EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
EP2734529A4 (en) | BTK INHIBITORS | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
EP2785183A4 (en) | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | |
ZA201206456B (en) | Uses of dgati inhibitors | |
IL231269B (en) | Preparations for the treatment of HIV | |
EP2776393A4 (en) | NAMPT INHIBITORS | |
HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
EP2521451A4 (en) | INHIBITORS OF THE HEDGEHOG PATH | |
HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
EP2688901A4 (en) | INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10 | |
PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
EP2663322A4 (en) | NEW USES OF CYCLOPHILIN INHIBITORS | |
GB201120474D0 (en) | Inhibitors | |
GB201104399D0 (en) | Novel inhibitors | |
GB201018597D0 (en) | Inhibitors | |
GB201006605D0 (en) | Novel inhibitors | |
GB201003936D0 (en) | Novel inhibitors | |
GB201003502D0 (en) | Novel inhibitors |